Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Fineline Cube May 9, 2026
Company Deals

Fosun Pharma Secures Exclusive China Rights to InxMed’s FAK Inhibitors for Solid Tumor Treatment

Fineline Cube May 9, 2026
Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Fineline Cube May 8, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors

Fineline Cube May 9, 2026
Company Drug

Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda

Fineline Cube May 9, 2026
Company Drug

Stemirna Therapeutics’ COVID-19 mRNA Vaccine Gets EUA in Laos

Fineline Cube Dec 12, 2022

Stemirna Therapeutics Co., Ltd, an mRNA drug developer based in Shanghai, has obtained Emergency Use...

Company Deals Digital

Medbanks Set for IPO on Hong Kong Stock Exchange

Fineline Cube Dec 12, 2022

Sipai Health Technology Co., Ltd, also known as Medbanks, is set to make an initial...

Company Drug

Fujian Cosunter Completes Enrollment for Phase I Study of GST-HG171

Fineline Cube Dec 12, 2022

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) announced the completion of the enrollment of...

Company Drug

Alphamab Oncology Updates Clinical Studies for KN046 and KN026 at SABCS 2022

Fineline Cube Dec 12, 2022

China-based Alphamab Oncology (HKG: 9966) updated the clinical studies for its KN046 and KN026 at...

Company Deals

Roche and Zhongshan Hospital Collaborate on Clinical Studies and Innovation Center

Fineline Cube Dec 12, 2022

Swiss giant Roche’s (SWX: ROG) China unit and Roche Diagnostics’ China unit entered into a...

Company Drug

ASH 2022: China Biotechs Showcase Latest Clinical Trial Results

Fineline Cube Dec 12, 2022

The American Society of Hematology (ASH) 2022 annual meeting, held online and offline in New...

Company Deals R&D

Merck Partners with Tsinghua Shenzhen for Organoid 3D Printing System

Fineline Cube Dec 12, 2022

Germany giant Merck (NYSE: MRK) struck a three-year partnership with Tsinghua Shenzhen International Graduate School,...

Company Deals

Luye Pharma Group Hands Over Seroquel Distribution Rights to DCH Auriga in Singapore

Fineline Cube Dec 12, 2022

China-based Luye Pharma Group announced that it is handing Singapore distribution and marketing rights to...

Company Drug

RemeGen’s RC118 Receives Orphan Drug Designations for Gastric and Pancreatic Cancers

Fineline Cube Dec 9, 2022

China-based RemeGen Ltd announced that its antibody drug conjugate (ADC) drug candidate RC118 has obtained...

Company Drug

Innovent Biologics Presents Clinical Study Results at ESMO-IO 2022

Fineline Cube Dec 9, 2022

China-based Innovent Biologics Inc. (HKG: 1801) announced the presentation of two clinical studies at the...

Policy / Regulatory

NMPA Extends Validation Period for COVID-19 Antigen Detection Reagents

Fineline Cube Dec 9, 2022

The National Medical Products Administration released a notification extending the validation period of approvals for...

Company Deals

Science Standard Medical Testing Raises Pre-Series A Funding

Fineline Cube Dec 9, 2022

Science Standard Medical Testing, a professional third-party testing institution based in Changzhou, reportedly raised “tens...

Company Deals

Phanes Therapeutics and BeiGene Partner on Phase I Study of PT199

Fineline Cube Dec 9, 2022

Sino-US biotech Phanes Therapeutics Inc. announced a clinical study cooperation and supply agreement with China-based...

Company Deals

XtalPi Partners with CTTQ for AI-Driven Small-Molecule Drug Development

Fineline Cube Dec 9, 2022

Sino-US artificial intelligence (AI) firm XtalPi Inc. struck a partnership with China-based Jiangsu Chia Tai...

Company Drug

Harbour BioMed Concludes Phase I Study for HBM4003 in Advanced Melanoma

Fineline Cube Dec 9, 2022

Harbour BioMed (HBM; HKG: 2142), a biotech operating out of the United States, the Netherlands,...

Company Deals

Frontier Biotechnologies Partners with Yuyue Med for FB2001 Atomizer

Fineline Cube Dec 9, 2022

China-based Frontier Biotechnologies Inc. (SHA: 688221) announced a strategic collaboration agreement with compatriot firm Jiangsu...

Company Deals

Harbour BioMed’s Nona Biosciences Licenses Antibody Platform to Kelun-Biotech

Fineline Cube Dec 9, 2022

Harbour BioMed (HKG: 2142), a biotech operating out of the Netherlands, the United States, and...

Company Deals

ExoNeuglia Secures Angel Funding for iPSC-Based Cell Therapy

Fineline Cube Dec 8, 2022

ExoNeuglia, a stem-cell-focused biotech based in Suzhou, reportedly raised “tens of millions” of renminbi in...

Company Drug

Jacobio’s KRAS G12C Inhibitor JAB-21822 Receives Breakthrough Therapy Designation

Fineline Cube Dec 8, 2022

The Center for Drug Evaluation (CDE) website indicates that China-based Jacobio Pharmaceuticals Group Co., Ltd’s...

Company Drug

CSPC and Ascletis Get NMPA Approval for COVID-19 Drug Clinical Trials

Fineline Cube Dec 8, 2022

China-based firms CSPC Pharmaceutical Group Ltd (HKG: 1093) and Ascletis Pharma Inc. (HKG: 1672) both...

Posts pagination

1 … 585 586 587 … 662

Recent updates

  • Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors
  • Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda
  • Ab&B Bio-Tech Secures NMPA Clinical Approval for mRNA RSV Vaccine, Addressing Critical Unmet Need in China
  • Mabwell Bioscience Secures FDA Clearance for 9MW5211 in IBD, Advances Multi-Indication Autoimmune Pipeline
  • Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors

Company Drug

Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda

Company Drug

Ab&B Bio-Tech Secures NMPA Clinical Approval for mRNA RSV Vaccine, Addressing Critical Unmet Need in China

Company Drug

Mabwell Bioscience Secures FDA Clearance for 9MW5211 in IBD, Advances Multi-Indication Autoimmune Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.